UNSPSC 51281818: Doxorubicin hydrochloride

This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82F2G7BL4E, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but more generally known as doxorubicin hydrochloride, which bears US NIH Compound Identifier 1691.

UNSPSC 51281818 Doxorubicin hydrochloride is a Commodity code for a specific oncology pharmaceutical product, but the recent state and local procurement activity under this code does not reflect purchases of doxorubicin itself. Instead, state and local health agencies are using this code tag for broader pharmaceutical procurement — including antibiotic tablets, naloxone, and drug deactivation systems — suggesting the code is being applied as a general pharmaceutical commodity marker rather than for the specific chemotherapy agent named. State and local issuing bodies deploying this code include county health departments and state health agencies soliciting through piggyback cooperative purchasing agreements and competitive bidding processes. The Illinois Department of Public Health has used the code for pharmaceutical warehouse orders through the MMCAP Infuse consortium, while Seminole County, Florida has tagged naloxone and drug deactivation system procurement with it.

Recent activity is geographically concentrated in Florida and Illinois. In June 2026, Seminole County, Florida released an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, with quarterly deliveries and a two-year initial term plus one-year renewal option. The Illinois Department of Public Health awarded a completed piggyback contract via MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for $2,999,999.11 over three years (12-month initial term plus two renewal years) for doxycycline hyclate and ciprofloxacin hydrochloride tablets. Bidders on active opportunities must submit electronic proposals, include all shipping and delivery costs, and comply with drug-free workplace certification and E-Verify requirements. The code shows limited recent activity and appears misaligned with its nominal scope, suggesting that state and local buyers tagging general pharmaceutical procurement may be using this code as a catch-all rather than for doxorubicin-specific purchases.